MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pemetrexed (Alimta)

A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.

Respiratory Medicine 2018 August [Link] Petrelli F, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini Ah3>Abstract Malignant plINTRODUCTION: Advanced malignant pleural mesothelioma (MPM) is generally treated with platinum/pemetrexed-based first-line therapy. Once the disease progresses, evidence for the efficacy of palliative treatments is lacking, and platinum re-challenge or single-agent […]

Comments Off on A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.

Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.

European Journal of Pharmaceutical Sciences 2018 July 17 [Link] Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, Petronini PG, Rusca M, Carbognani P, Ampoll Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by a long latency period of 20-50 years after exposure to the main aetiology agent that is asbestos. […]

Comments Off on Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.

British Journal of Cancer 2018 June 20 [Link] Xu D, Liang SQ, Yang H, Lüthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW Abstract BACKGROUND: Standard treatment for advanced malignant pleural mesothelioma (MPM) is a cisplatin/pemetrexed (MTA) regimen; however, this is confronted by drug resistance. Proteotoxic […]

Comments Off on Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Clinical Lung Cancer 2018 May 9 [Link] Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K

Comments Off on A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

BMC Cancer 2018 April [Link] Giger-Pabst, Demtröder, Falkenstein, Ouaissi, Götze, Rezniczek, Tempfer Abstract BACKGROUND: Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options. METHODS: We performed a retrospective cohort study of patients with recurrent MM undergoing Pressurized IntraPeritoneal/Thoracal Aerosol Chemotherapy (PIPAC/PITAC) with doxorubicin 1.5 mg/m2 and cisplatin 7.5 mg/m2. […]

Comments Off on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 Februrary [Link] Oehl K et. al. Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 February [Link] Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

Cancer Medicine 2018 February 26 [Epub ahead of print] [Link] Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC Abstract This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density, […]

Comments Off on Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

BMC Cancer 2018 February 17 [Link] de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA Abstract BACKGROUND: Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in the […]

Comments Off on A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Annals of Surgical Oncology 2018 February [Epub ahead of print] [Link] Alexander HR Jr., Li CY, Kennedy TJ Abstract PURPOSE: Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity […]

Comments Off on Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma